Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selvita Extends Collaboration with Chiesi Farmaceutici

Published: Monday, January 13, 2014
Last Updated: Monday, January 13, 2014
Bookmark and Share
Collaboration started with fee-for-service chemical synthesis in 2011.

Selvita has extended its chemistry research collaboration with Chiesi Farmaceutici from Italy.

“We are very proud to be working for such renowned and innovative company as Chiesi. Chiesi projects always involve novel, challenging chemistry and they let us demonstrate the full potential of Selvita’s chemistry team, our broad knowledge, experience and skills.” said Dr Miroslawa Zydron, Director of Contract Chemistry Department at Selvita.

The collaboration between Chiesi and Selvita started with fee-for-service chemical synthesis in 2011. After the successful completion of several projects, it evolved into FTE-based collaboration in 2012-2013.

The joint projects support Chiesi proprietary drug discovery and development pipeline, which is focused on respiratory, cardiovascular and special care disorders.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selvita Opens New Research Site in Poznan
New site will be located at in the Wielkopolska Centre of Advanced Technologies.
Friday, February 05, 2016
Merck and Selvita Announce Drug Discovery Collaboration
Focus is to discover small molecule lead candidates for multiple oncology indications.
Tuesday, November 03, 2015
Selvita Launches New Company
Bioinformatics and personalized medicine focused Ardigen.
Friday, September 25, 2015
Selvita Establishes its First Operations in the U.S.
The largest drug discovery company in Central and Eastern Europe opens offices in Cambridge, MA and San Bruno, CA.
Saturday, September 19, 2015
Selvita Team Grows to Over 250 People
The company will publish its results for H1 2015 on August 13, 2015.
Tuesday, August 11, 2015
Selvita Establishes its UK Subsidiary in Cambridge
New office will be responsible for supporting the ongoing projects for the UK and Northern Ireland customers.
Thursday, May 07, 2015
Selvita Initiates IND-enabling Studies for its First-In-Class PIM/FLT3 Inhibitor
Company has signed agreement with Aptuit for the preparation of selected studies for the IND/CTA data package.
Saturday, April 04, 2015
Selvita Expands its Proteomics Services Offer
Expansion includes highly sophisticated mass spectrometers, additional ultra HPLC systems; and microscale thermophoresis measurement devices.
Wednesday, March 25, 2015
Selvita Group Received a GMP Certificate
Certificate was issued for 3 years.
Wednesday, February 19, 2014
Selvita Announces Changes to Management Board
Company announces appointment of Dr. Miroslawa Zydron and Dr. Krzysztof Brzozka.
Wednesday, November 06, 2013
Selvita and Orion Pharma Achieve a Research Milestone in Alzheimer’s Disease Program
Selvita is responsible for early research on the program.
Monday, July 02, 2012
Selvita Signs Contract with Evestra
Delivery of a range of drug metabolism, pharmacokinetic and physicochemical studies.
Tuesday, September 27, 2011
Selvita Signs a Computational Chemistry Services Agreement with IPD, USA
Agreement aims to identify novel chemical compounds that inhibit the activity of a novel protein target, proposed by IPD.
Wednesday, April 06, 2011
Selvita Signs a Drug Discovery Services Contract with Rottapharm Madaus
The project is aimed to deliver Rottapharm Madaus a set of designed and synthesized compounds having therapeutic potential in an indicated area.
Thursday, July 22, 2010
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!